VistaGen Therapeutics, Inc.(VTGN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

VTGN VistaGen Therapeutics, Inc.

交易中 07-15 10:03:24 EDT

0.2420

-0.0041

-1.67%

最高0.2460	最低0.2402	成交量1.93万
今开0.2460	昨收0.2461	日振幅2.36%
总市值992.99万	流通市值914.93万	总股本4,103万
成交额4,688	换手率0.05%	流通股本3,781万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"VTGN","market":"US","secType":"STK","nameCN":"VistaGen Therapeutics, Inc.","latestPrice":0.242,"timestamp":1784124103871,"preClose":0.2461,"halted":0,"volume":19327,"delay":0,"changeRate":-0.016659894351889557,"floatShares":37807045,"shares":41032453,"eps":-1.830255,"marketStatus":"交易中","change":-0.0041,"latestTime":"07-15 10:03:24 EDT","open":0.246,"high":0.246,"low":0.2402,"amount":4688.49730965,"amplitude":0.023568,"askPrice":0.2449,"askSize":500,"bidPrice":0.24,"bidSize":9640,"shortable":3,"etf":0,"ttmEps":-1.830255,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1784145600000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1462939200000,"exchange":"NASDAQ","adjPreClose":0.2461,"preHourTrading":{"tag":"盘前","latestPrice":0.246,"preClose":0.2461,"latestTime":"08:42 EDT","volume":1000,"amount":246,"timestamp":1784119352961,"change":-0.0001,"changeRate":-0.000406,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":0.24,"preClose":0.2461,"latestTime":"19:54 EDT","volume":998,"amount":239.4519,"timestamp":1784073254207,"change":-0.0061,"changeRate":-0.024787,"amplitude":0.065014},"volumeRatio":0.127914,"impliedVol":3.512,"impliedVolPercentile":0.9084},"requestUrl":"/m/hq/s/VTGN","defaultTab":"news","newsList":[{"id":"1106146048","title":"VistaGen公布Fasedienol治疗社交焦虑症的Palisade-4三期公众演讲挑战试验顶线及事后分析数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1106146048","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106146048?lang=zh_cn&edition=full","pubTime":"2026-07-06 15:26","pubTimestamp":1783322808,"startTime":"0","endTime":"0","summary":"VistaGen Therapeutics Inc.宣布了其候选药物Fasedienol用于社交焦虑症急性治疗的Palisade-4三期公众演讲挑战试验的顶线结果及事后分析数据。试验数据显示，Fasedienol在主要和次要终点上均未达到统计学意义上的显著改善。\n然而，该药物的安全性和耐受性数据良好，与先前的临床试验结果保持一致。\n公司计划与美国食品药品监督管理局（FDA）会面，就Fasedienol的未来三期试验及注册路径进行讨论。\n值得注意的是，一项事后分析表明，在非常严重的社交焦虑症患者亚组中，Fasedienol显示出名义上的统计学显著性。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VTGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142107877","title":"VistaGen公司事后分析显示，Fasedienol在极重度社恐亚组中达到名义统计显著性","url":"https://stock-news.laohu8.com/highlight/detail?id=1142107877","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142107877?lang=zh_cn&edition=full","pubTime":"2026-06-30 20:03","pubTimestamp":1782821010,"startTime":"0","endTime":"0","summary":"VistaGen Therapeutics 公布的一项事后分析结果显示，其候选药物 Fasedienol 在针对极重度社交焦虑障碍亚组患者的研究中，达到了名义上的统计学显著性。该分析聚焦于病情程度最为严重的患者群体，数据显示，与安慰剂相比，Fasedienol 在这一特定亚组中展现出具有前景的疗效信号。名义统计显著性意味着，在未对多重检验进行调整的情况下，结果达到了预设的统计阈值。这一发现为 Fasedienol 的后续临床开发路径提供了新的见解。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VTGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128069424","title":"VistaGen公布Fasedienol治疗社交焦虑障碍急性期Palisade-4三期公开演讲挑战试验的顶线及事后分析数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1128069424","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128069424?lang=zh_cn&edition=full","pubTime":"2026-06-30 20:01","pubTimestamp":1782820910,"startTime":"0","endTime":"0","summary":"VistaGen Therapeutics, Inc. (VTGN) 公布了其候选药物Fasedienol用于社交焦虑障碍急性期治疗的三期临床试验Palisade-4的顶线数据及事后分析结果。该试验采用公开演讲挑战模型进行评估。\n数据显示，在主要终点和关键次要终点上，Fasedienol治疗组与安慰剂组相比，未达到统计学显著性差异。然而，公司进行的探索性事后分析指出，在预先设定的亚组人群中观察到了具有临床意义的改善信号。\n此次公布的数据为后续临床开发策略提供了重要参考。公司表示将继续深入分析完整数据集，以进一步明确Fasedienol的潜在治疗价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VTGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150037136","title":"VistaGen Therapeutics公司：Fasedienol在主要及次要终点上未实现统计学显著改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1150037136","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150037136?lang=zh_cn&edition=full","pubTime":"2026-06-30 20:01","pubTimestamp":1782820902,"startTime":"0","endTime":"0","summary":"VistaGen Therapeutics, Inc. (VTGN) 近日公布，其候选药物Fasedienol在关键临床试验中，未能于主要及次要疗效终点上展现出统计学意义上的显著改善。这一结果标志着该药物在特定治疗路径上遭遇了重大挫折，引发了市场对公司研发管线进展的重新评估。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VTGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168620088","title":"VistaGen计划与FDA会晤，探讨Fasedienol的注册路径及未来三期试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1168620088","media":"美股速递","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168620088?lang=zh_cn&edition=full","pubTime":"2026-06-30 20:01","pubTimestamp":1782820900,"startTime":"0","endTime":"0","summary":"VistaGen Therapeutics公司宣布，计划与美国食品药品监督管理局（FDA）会面，商讨其候选药物Fasedienol的注册申报路径以及未来的三期临床试验规划。此次会议旨在为后续的临床开发与监管提交确定清晰的路线图。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VTGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109937075","title":"VistaGen Therapeutics公布积极安全性及耐受性数据 与既往临床试验结果一致","url":"https://stock-news.laohu8.com/highlight/detail?id=1109937075","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109937075?lang=zh_cn&edition=full","pubTime":"2026-06-30 20:01","pubTimestamp":1782820894,"startTime":"0","endTime":"0","summary":"VistaGen Therapeutics披露的最新数据显示，其药物在安全性及耐受性方面的表现令人鼓舞，这一结果与先前开展的临床试验所得结论高度吻合。该积极数据进一步巩固了公司研发管线的可靠性，为后续的临床开发路径提供了有力支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VTGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114884667","title":"VistaGen Therapeutics, Inc. 旗下Fasedienol鼻喷雾剂耐受性良好，12个月后无新增安全性发现","url":"https://stock-news.laohu8.com/highlight/detail?id=1114884667","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114884667?lang=zh_cn&edition=full","pubTime":"2026-05-12 19:31","pubTimestamp":1778585476,"startTime":"0","endTime":"0","summary":"VistaGen Therapeutics, Inc. 宣布，其Fasedienol鼻喷雾剂在为期12个月的观察期内展现出良好的耐受性，未发现新的安全性问题。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VTGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172520288","title":"Vistagen披露Palisade-3三期研究开放标签扩展部分初步积极数据，Fasedienol用于社交焦虑障碍急性治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1172520288","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172520288?lang=zh_cn&edition=full","pubTime":"2026-05-12 19:31","pubTimestamp":1778585475,"startTime":"0","endTime":"0","summary":"Vistagen公司宣布，在其Palisade-3三期研究中，关于Fasedienol用于社交焦虑障碍急性治疗的开放标签扩展部分，获得了初步的积极数据。这项研究目前仍在进行中。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VTGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100851891","title":"VistaGen获FDA批准开展Refisolone新药临床研究，推进更年期血管舒缩症状（潮热）二期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1100851891","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100851891?lang=zh_cn&edition=full","pubTime":"2026-04-22 20:35","pubTimestamp":1776861341,"startTime":"0","endTime":"0","summary":"VistaGen Therapeutics宣布，美国食品药品监督管理局（FDA）已就其Refisolone新药临床申请发出“研究可继续进行”许可函，这意味着公司可进一步开展针对更年期引发的血管舒缩症状（即潮热）的二期临床开发计划。\n此次监管绿灯为Refisolone的临床推进扫清了关键障碍，标志着该创新疗法在解决更年期女性潮热问题方面迈出实质性一步。公司计划基于这一许可加速推进二期临床试验，探索Refisolone在缓解更年期相关症状方面的潜力与安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VTGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187789740","title":"VistaGen Therapeutics披露：被裁员工或获现金遣散费及临时医保","url":"https://stock-news.laohu8.com/highlight/detail?id=1187789740","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187789740?lang=zh_cn&edition=full","pubTime":"2026-03-11 19:07","pubTimestamp":1773227259,"startTime":"0","endTime":"0","summary":"根据最新提交至美国证券交易委员会（SEC）的文件显示，生物制药公司VistaGen Therapeutics, Inc. 正为其裁员计划中的受影响员工提供补偿方案。该方案可能包括一次性现金遣散费以及过渡期的医疗保险覆盖。\n这一举措反映了公司在业务调整过程中对员工权益的保障。通过提供经济补偿和延续医疗保障，VistaGen旨在减轻岗位变动对员工生活的短期冲击。SEC文件披露的细节表明，公司已就裁员补偿制定了具体实施框架。\n（注：根据公开信息，VistaGen Therapeutics为临床阶段生物制药企业，专注于开发新型神经科学疗法。此次人员调整或与公司战略重心优化相关。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VTGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143674821","title":"VistaGen Therapeutics第三季度每股收益$(0.46)超出预期$(0.51)，销售额23.4万美元超出预期18万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1143674821","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143674821?lang=zh_cn&edition=full","pubTime":"2025-02-14 05:44","pubTimestamp":1739483087,"startTime":"0","endTime":"0","summary":"与去年同期的每股亏损$相比，这是109.09%的下降。公司报告季度销售额为23.4万美元，超出分析师一致预期的18万美元，高出30%。与去年同期的41.14万美元相比，这一数据下降了43.12%。以上内容来自Benzinga Earnings专栏，原文如下：VistaGen $Therapeutics$  reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 9.8 percent. This is a 109.09 percent decrease over losses of $ per share from the same period last year.  The company reported quarterly sales of $234.00 thousand which beat the analyst consensus estimate of $180.00 thousand by 30.00 percent.  This is a ","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"VistaGen Therapeutics第三季度每股收益$(0.46)超出预期$(0.51)，销售额23.4万美元超出预期18万美元","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VTGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2507467790","title":"Vistagen Therapeutics, Inc.盘中异动 大幅拉升5.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2507467790","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2507467790?lang=zh_cn&edition=full","pubTime":"2025-01-31 04:05","pubTimestamp":1738267529,"startTime":"0","endTime":"0","summary":"北京时间2025年01月31日04时05分，Vistagen Therapeutics, Inc.股票出现波动，股价大幅上涨5.59%。截至发稿，该股报3.02美元/股，成交量7.4433万股，换手率0.27%，振幅6.56%。Vistagen Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.39%。其相关个股中，Tectonic Therapeutic, Inc.、Alterity Therapeutics Limited、Dominari Holdings Inc.涨幅较大，Kazia Therapeutics Limited、Silexion Therapeutics Corp、Alterity Therapeutics Limited较为活跃，换手率分别为1808.61%、328.29%、253.64%，振幅较大的相关个股有Dominari Holdings Inc.、Cero Therapeutics Holdings, Inc.、Immatics N V C/Wts 01/07/2025 ，振幅分别为70.55%、65.98%、64.10%。Vistagen Therapeutics, Inc.公司简介：VistaGen Therapeutics Inc是一家生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501310405299876d5ca&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501310405299876d5ca&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","VTGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2504816292","title":"Vistagen Therapeutics, Inc.盘中异动 股价大涨6.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2504816292","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2504816292?lang=zh_cn&edition=full","pubTime":"2025-01-17 22:32","pubTimestamp":1737124343,"startTime":"0","endTime":"0","summary":"北京时间2025年01月17日22时32分，Vistagen Therapeutics, Inc.股票出现波动，股价快速上涨6.16%。截至发稿，该股报3.10美元/股，成交量1.0667万股，换手率0.04%，振幅6.16%。Vistagen Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.68%。其相关个股中，Channel Therapeutics Corporation、Immuron Limited、Revance Therapeutics, Inc.涨幅较大，Aditxt, Inc.、Aeon Biopharma, Inc.、Bioline Rx Ltd较为活跃，换手率分别为92.11%、14.24%、6.82%，振幅较大的相关个股有Immatics N V C/Wts 01/07/2025 、天境生物、Jupiter Neurosciences, Inc.，振幅分别为25.26%、10.00%、9.84%。Vistagen Therapeutics, Inc.公司简介：VistaGen Therapeutics Inc是一家生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250117223223a225bc25&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250117223223a225bc25&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","VTGN","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2487256146","title":"Vistagen Therapeutics, Inc.盘中异动 早盘快速拉升5.20%报2.83美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2487256146","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2487256146?lang=zh_cn&edition=full","pubTime":"2024-11-30 00:26","pubTimestamp":1732897566,"startTime":"0","endTime":"0","summary":"北京时间2024年11月30日00时26分，Vistagen Therapeutics, Inc.股票出现异动，股价大幅拉升5.20%。截至发稿，该股报2.83美元/股，成交量4.018万股，换手率0.14%，振幅5.76%。Vistagen Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.30%。其相关个股中，Klotho Neurosciences Inc C/Wts 21/06/2029 、Silexion Therapeutics Corp C/Wts Exp 15/08/2029 、Passage Bio, Inc.涨幅较大，Silo Pharma, Inc.、Klotho Neurosciences, Inc.、Tc Biopharm  Plc较为活跃，换手率分别为176.47%、70.13%、62.72%，振幅较大的相关个股有Cingulate Inc C/Wts 10/12/2026 、Klotho Neurosciences, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 ，振幅分别为130.29%、105.44%、68.75%。Vistagen Therapeutics, Inc.公司简介：VistaGen Therapeutics Inc是一家生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024113000260698e46ad5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024113000260698e46ad5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VTGN","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2486036873","title":"Vistagen Therapeutics, Inc.盘中异动 早盘快速拉升5.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2486036873","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486036873?lang=zh_cn&edition=full","pubTime":"2024-11-25 23:26","pubTimestamp":1732548389,"startTime":"0","endTime":"0","summary":"北京时间2024年11月25日23时26分，Vistagen Therapeutics, Inc.股票出现波动，股价急速上涨5.43%。截至发稿，该股报2.72美元/股，成交量5.9138万股，换手率0.21%，振幅4.65%。Vistagen Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为2.08%。其相关个股中，Alpha Tau Medical Ltd C/Wts 、Ocean Biomedical Inc C/Wts 14/02/2028 、Exicure, Inc.涨幅较大，木薯科学、Cognition Therapeutics, Inc.、Citius Pharmaceuticals, Inc.较为活跃，换手率分别为102.20%、99.15%、57.18%，振幅较大的相关个股有Apollomics Inc C/Wts 01/04/2028 、180 Life Sciences Corp C/Wts 07/11/2025、Exicure, Inc.，振幅分别为71.29%、65.85%、49.39%。Vistagen Therapeutics, Inc.公司简介：VistaGen Therapeutics Inc是一家生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241125232629971a8688&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241125232629971a8688&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","VTGN","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2484783510","title":"Vistagen Therapeutics, Inc.2024财年第三财季实现净利润-12.96百万美元，同比减少96.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484783510","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484783510?lang=zh_cn&edition=full","pubTime":"2024-11-17 00:03","pubTimestamp":1731773008,"startTime":"0","endTime":"0","summary":"11月17日，Vistagen Therapeutics, Inc.公布财报，公告显示公司2024财年第三财季净利润为-12.96百万美元，同比减少96.66%；其中营业收入为183000.00美元，同比减少34.10%，每股基本收益为-0.42美元。从资产负债表来看，Vistagen Therapeutics, Inc.总负债9.52百万美元，其中短期债务525000.00美元，资产负债比为0.11，流动比率为13.30。机构评级：截至2024年11月17日，当前有3家机构对Vistagen Therapeutics, Inc.目标价做出预测，其中目标均价为13.00美元，其中最低目标价为12.00美元，最高目标价为15.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241117000441abc79103&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241117000441abc79103&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","VTGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2483630037","title":"Vistagen Therapeutics, Inc.盘中异动 快速下挫5.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483630037","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483630037?lang=zh_cn&edition=full","pubTime":"2024-11-13 02:20","pubTimestamp":1731435647,"startTime":"0","endTime":"0","summary":"北京时间2024年11月13日02时20分，Vistagen Therapeutics, Inc.股票出现异动，股价大幅跳水5.29%。截至发稿，该股报2.86美元/股，成交量10.7255万股，换手率0.40%，振幅5.30%。Vistagen Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.86%。其相关个股中，60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Genprex, Inc.、Kairos Pharma, Ltd.涨幅较大，Genprex, Inc.、Cero Therapeutics Holdings, Inc.、Elevai Labs, Inc.较为活跃，换手率分别为531.01%、426.42%、228.80%，振幅较大的相关个股有60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Geovax Labs Inc C/Wts 29/09/2025、Neurosense Therapeutics Ltd C/Wts 10/11/2026 ，振幅分别为209.30%、105.45%、86.87%。Vistagen Therapeutics, Inc.公司简介：VistaGen Therapeutics Inc是一家生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111302204798e4227a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111302204798e4227a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","VTGN","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2473484671","title":"Vistagen Therapeutics, Inc.盘中异动 下午盘急速下跌5.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2473484671","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2473484671?lang=zh_cn&edition=full","pubTime":"2024-10-08 02:15","pubTimestamp":1728324911,"startTime":"0","endTime":"0","summary":"北京时间2024年10月08日02时15分，Vistagen Therapeutics, Inc.股票出现波动，股价大幅下挫5.32%。截至发稿，该股报2.85美元/股，成交量10.9968万股，换手率0.41%，振幅4.98%。Vistagen Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.24%。其相关个股中，Scholar Rock Holding Corporation、Nls Pharmaceutics Ltd C/Wts 02/02/2026、Oncolytics Biotech Inc.涨幅较大，Aditxt, Inc.、Tc Biopharm  Plc、Phio Pharmaceuticals Corp.较为活跃，换手率分别为1628.95%、82.93%、60.41%，振幅较大的相关个股有Scholar Rock Holding Corporation、Reviva Pharmaceuticals Holdings Inc C/Wts 25/12/2025、Akari Therapeutics Plc，振幅分别为107.82%、39.46%、37.93%。Vistagen Therapeutics, Inc.公司简介：VistaGen Therapeutics Inc是一家生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241008021511ab68223a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241008021511ab68223a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","VTGN"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vistagen.com","stockEarnings":[{"period":"1week","weight":0.0388},{"period":"1month","weight":-0.5729},{"period":"3month","weight":-0.5975},{"period":"6month","weight":-0.6332},{"period":"1year","weight":-0.8966},{"period":"ytd","weight":-0.6282}],"compareEarnings":[{"period":"1week","weight":0.0055},{"period":"1month","weight":0.0136},{"period":"3month","weight":0.0741},{"period":"6month","weight":0.0861},{"period":"1year","weight":0.2033},{"period":"ytd","weight":0.1025}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Vistagen Therapeutics, Inc.于1998年5月26日注册成立。该公司是一家处于临床后期阶段的治疗公司，专注于开发用于社交焦虑症、抑郁症、更年期潮热、精神疲劳引起的精神运动障碍以及癌症恶病质的药物。其管线包括鼻内给予的pherine候选产品，设计用于结合鼻腔化学感觉神经元中的外周受体，并在无需全身吸收的情况下激活调节脑区的神经回路。最领先的候选产品fasedienol正在美国进行社交焦虑症的3期临床项目。其他候选产品包括用于抑郁症的itruvone、用于更年期潮热的refisolone、用于精神运动障碍的PH15以及用于癌症恶病质的PH284。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.126859},{"month":2,"riseRate":0.3,"avgChangeRate":-0.102734},{"month":3,"riseRate":0.2,"avgChangeRate":-0.108038},{"month":4,"riseRate":0.6,"avgChangeRate":0.018256},{"month":5,"riseRate":0.6,"avgChangeRate":0.003251},{"month":6,"riseRate":0.272727,"avgChangeRate":-0.136963},{"month":7,"riseRate":0.363636,"avgChangeRate":-0.01619},{"month":8,"riseRate":0.8,"avgChangeRate":0.268993},{"month":9,"riseRate":0.3,"avgChangeRate":0.032968},{"month":10,"riseRate":0.5,"avgChangeRate":-0.061688},{"month":11,"riseRate":0.4,"avgChangeRate":-0.060004},{"month":12,"riseRate":0.7,"avgChangeRate":0.164554}],"exchange":"NASDAQ","name":"VistaGen Therapeutics, Inc.","nameEN":"VistaGen Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"VistaGen Therapeutics, Inc.(VTGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供VistaGen Therapeutics, Inc.(VTGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"VistaGen Therapeutics, Inc.,VTGN,VistaGen Therapeutics, Inc.股票,VistaGen Therapeutics, Inc.股票老虎,VistaGen Therapeutics, Inc.股票老虎国际,VistaGen Therapeutics, Inc.行情,VistaGen Therapeutics, Inc.股票行情,VistaGen Therapeutics, Inc.股价,VistaGen Therapeutics, Inc.股市,VistaGen Therapeutics, Inc.股票价格,VistaGen Therapeutics, Inc.股票交易,VistaGen Therapeutics, Inc.股票购买,VistaGen Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"VistaGen Therapeutics, Inc.(VTGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供VistaGen Therapeutics, Inc.(VTGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}